Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

por Negoescu, Andra F., Östör, Andrew J. K.
Publicado 2014

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician

por Findeisen, Kate E, Sewell, Julia, Ostor, Andrew J K
Publicado 2021

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals

por Kiely, Patrick D. W., Deighton, Chris, Dixey, Josh, Östör, Andrew J. K.
Publicado 2012

Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review

por Ostor, Andrew J., Sawant, Ruta, Qi, Cynthia Z., Wu, Aozhou, Nagy, Orsolya, Betts, Keith A.
Publicado 2021

Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study

por Van den Bosch, Filip, Ostor, Andrew J. K., Wassenberg, Siegfried, Chen, Naijun, Wang, Chen, Garg, Vishvas, Kalabic, Jasmina
Publicado 2017

Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study

por Van den Bosch, Filip, Ostor, Andrew J. K., Wassenberg, Siegfried, Chen, Naijun, Wang, Chen, Garg, Vishvas, Kalabic, Jasmina
Publicado 2017

Tetrahydrobiopterin Supplementation Improves Endothelial Function But Does Not Alter Aortic Stiffness in Patients With Rheumatoid Arthritis

por Mäki‐Petäjä, Kaisa M., Day, Lisa, Cheriyan, Joseph, Hall, Frances C., Östör, Andrew J. K., Shenker, Nicholas, Wilkinson, Ian B.
Publicado 2016

Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2

por Ostor, Andrew J K, Soliman, Ahmed M, Papp, Kim A, Padilla, Byron, Wang, Zailong, Eldred, Ann, de Vlam, Kurt, Kivitz, Alan
Publicado 2022

Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: Addressing treatment outside the current N...

por Chiu, Yee, Ostor, Andrew J. K., Hammond, Anthony, Sokoll, Katharina, Anderson, Marina, Buch, Maya, Ehrenstein, Michael R., Gordon, Patrick, Steer, Sophia, Bruce, Ian N.
Publicado 2012

A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases

por Vangeli, Eleni, Bakhshi, Savita, Baker, Anna, Fisher, Abigail, Bucknor, Delaney, Mrowietz, Ulrich, Östör, Andrew J. K., Peyrin-Biroulet, Laurent, Lacerda, Ana P., Weinman, John
Publicado 2015

Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies

por Cooles, Faye A. H., Anderson, Amy E., Drayton, Tracey, Harry, Rachel A., Diboll, Julie, Munro, Lee, Thalayasingham, Nishanthi, Östör, Andrew J. K., Isaacs, John D.
Publicado 2016

Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice

por Bykerk, Vivian P, Östör, Andrew J K, Alvaro-Gracia, José, Pavelka, Karel, Ivorra, José Andrés Román, Graninger, Winfried, Bensen, William, Nurmohamed, Michael T, Krause, Andreas, Bernasconi, Corrado, Stancati, Andrea, Sibilia, Jean
Publicado 2012

Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments:...

por Bykerk, Vivian P., Östör, Andrew J. K., Alvaro-Gracia, José, Pavelka, Karel, Ivorra, José Andrés Román, Graninger, Winfried, Bensen, William, Nurmohamed, Michael T., Krause, Andreas, Bernasconi, Corrado, Aassi, Maher, Sibilia, Jean
Publicado 2015

Erratum to: Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous...

por Bykerk, Vivian P., Östör, Andrew J. K., Alvaro-Gracia, José, Pavelka, Karel, Ivorra, José Andrés Román, Graninger, Winfried, Bensen, William, Nurmohamed, Michael T., Krause, Andreas, Bernasconi, Corrado, Aassi, Maher, Sibilia, Jean
Publicado 2015

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

por van der Heijde, Désirée, Deodhar, Atul, Maksymowych, Walter P, Sieper, Joachim, Van den Bosch, Filip, Kim, Tae-Hwan, Kishimoto, Mitsumasa, Östör, Andrew J, Combe, Bernard, Sui, Yunxia, Duan, Yuanyuan, Wung, Peter K, Song, In-Ho
Publicado 2022

Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials

por McInnes, Iain B, Ostor, Andrew J K, Mease, Philip J, Tillett, William, Baraliakos, Xenofon, de Vlam, Kurt, Bessette, Louis, Lippe, Ralph, Maniccia, Anna, Feng, Dai, Gao, Tianming, Zueger, Patrick, Saffore, Christopher, Kato, Koji, Song, In-Ho, Deodhar, Atul
Publicado 2022